Wednesday, October 26, 2022 6:53:34 PM
A couple of things from your post. Yes, year over year they have diluted roughly 40 million shares. The shares authorized was 190 million, since June is now far higher as you well know.
But the truth is who cares. Until this company finds a way to sell more product {a lot more} it doesn’t matter. Unless somebody gets excited about being in the 4 cents, give or take a penny or two range there is just nothing there to grow with. Sure, they are still selling product, and sure the dollars they take in is falling. THEY ARE DILUTING TO STAY IN BUSINESS, and with out a complete overhaul of the failed leadership {again were at a little less than .04 cents} to be fair the 4 cents mark didn’t happen until May, that still 6 mo. of hugging that range, a few weeks higher’ lower but still comes back to .04. and yes, I feel it’s the leadership holding this back. Diluting is NOT the main factor on why this company is failing. So again, who cares. IMO
But the truth is who cares. Until this company finds a way to sell more product {a lot more} it doesn’t matter. Unless somebody gets excited about being in the 4 cents, give or take a penny or two range there is just nothing there to grow with. Sure, they are still selling product, and sure the dollars they take in is falling. THEY ARE DILUTING TO STAY IN BUSINESS, and with out a complete overhaul of the failed leadership {again were at a little less than .04 cents} to be fair the 4 cents mark didn’t happen until May, that still 6 mo. of hugging that range, a few weeks higher’ lower but still comes back to .04. and yes, I feel it’s the leadership holding this back. Diluting is NOT the main factor on why this company is failing. So again, who cares. IMO
Recent CVSI News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2026 08:10:09 PM
- CV Sciences, Inc. Reports First Quarter-End 2026 Financial Results • ACCESS Newswire • 05/14/2026 08:00:00 PM
- CV Sciences, Inc. To Announce First Quarter 2026 Results On May 14, 2026 • ACCESS Newswire • 05/12/2026 10:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/10/2026 08:04:10 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/26/2026 09:14:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/26/2026 08:06:03 PM
- CV Sciences, Inc. Reports Fiscal Year-End 2025 Financial Results • ACCESS Newswire • 03/26/2026 08:00:00 PM
- CV Sciences, Inc. To Announce Year End and Fourth Quarter 2025 Results On March 26, 2026 • ACCESS Newswire • 03/24/2026 09:00:00 PM
- CV Sciences Announces Successful Debt Restructuring Designed to Strengthen Financial Position and Fuel Future Growth • ACCESS Newswire • 03/10/2026 09:00:00 PM
- CV Sciences Launches EMPOWR: A Plant-Based Protein + Creatine Formula Designed for Total Wellness • ACCESS Newswire • 02/26/2026 01:30:00 PM
- CV Sciences, Inc. Positioned to Participate in the Medicare and Medicaid Pilot Program for CBD • ACCESS Newswire • 12/23/2025 12:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2025 10:19:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2025 09:04:08 PM
- CV Sciences, Inc. Reports Third Quarter 2025 Financial Results • ACCESS Newswire • 11/13/2025 09:00:00 PM
- CV Sciences, Inc. to Announce Third Quarter 2025 Results on November 13, 2025 • ACCESS Newswire • 11/10/2025 11:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/10/2025 09:05:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/18/2025 08:24:23 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2025 09:23:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2025 08:01:09 PM
